Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05919264 · ClinicalTrials.gov registry record · Phase 1
FOG-001 in Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Cancer and Colorectal Cancer, sponsored by Parabilis Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 575
- Enrollment target
- 20
- Study locations
NCT05919264 is a Phase 1 study of Cancer and Colorectal Cancer that is actively recruiting participants, run by Parabilis Medicines. The registered enrollment target is 575 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT05919264, a Phase 1 study of Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by Parabilis Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 575 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic cancer.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Nivolumab
- DRUG FOG-001
- DRUG mFOLFOX-6
- DRUG Trifluridine/tipiracil
Study Locations (20)
California
- Stanford Cancer Institute, Stanford University - Palo Alto
- University of California San Francisco, Helen Diller Family Comprehensive Cancer Center - San Francisco
- Sarcoma Oncology Center - Santa Monica
Arizona
- Honor Health - Scottsdale
- Arizona Cancer Center at University of Arizona - Tucson
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Ohio
- University Hospitals Cleveland Medical Center, Seidman Cancer Center - Cleveland
- Cleveland Clinic - Cleveland
Connecticut
- Yale University School of Medicine - New Haven
District of Columbia
- Johns Hopkins University, Sibley Memorial Hospital - Washington D.C.
Florida
- Florida Cancer Specialists - Lake Mary
Maryland
- Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 575 participants |
| Start Date | 2023-05-23 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05919264
The ClinicalTrials.gov registry entry for NCT05919264 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 575 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (84% lower). The listed sponsor is Parabilis Medicines, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT05919264 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Arizona, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05919264 about?
NCT05919264 is a clinical study titled "FOG-001 in Locally Advanced or Metastatic Solid Tumors". The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic cancer.
What is the current status of trial NCT05919264?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 575 participants. The study started on 2023-05-23. Estimated completion is 2027-08-31.
What conditions does trial NCT05919264 study?
This clinical trial studies the following conditions: Cancer, Colorectal Cancer, Solid Tumor, Metastatic Cancer, Locally Advanced Solid Tumor.
What interventions are being tested in trial NCT05919264?
The interventions under investigation include: Bevacizumab (DRUG), Nivolumab (DRUG), FOG-001 (DRUG), mFOLFOX-6 (DRUG), Trifluridine/tipiracil (DRUG).
Who is sponsoring clinical trial NCT05919264?
This trial is sponsored by Parabilis Medicines, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05919264 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.